Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Capital Expenditures (2016 - 2025)

Vistagen Therapeutics' Capital Expenditures history spans 13 years, with the latest figure at $143000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 38.83% year-over-year to $143000.0; the TTM value through Dec 2025 reached $48000.0, down 57.89%, while the annual FY2024 figure was $29000.0, N/A changed from the prior year.
  • Capital Expenditures for Q4 2025 was $143000.0 at Vistagen Therapeutics, up from -$22000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $200400.0 in Q3 2021 and bottomed at -$103000.0 in Q1 2025.
  • The 4-year median for Capital Expenditures is $27750.0 (2021), against an average of $46316.7.
  • The largest annual shift saw Capital Expenditures soared 472.22% in 2024 before it tumbled 1036.36% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at $200400.0 in 2021, then tumbled by 91.02% to $18000.0 in 2023, then skyrocketed by 472.22% to $103000.0 in 2024, then surged by 38.83% to $143000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Capital Expenditures are $143000.0 (Q4 2025), -$22000.0 (Q3 2025), and $30000.0 (Q2 2025).